Blood Screening Market

Blood Screening Market Analysis

The blood screening market is valued at USD 3.24 billion in 2025 and is forecast to reach USD 4.86 billion by 2030 at an 8.42% CAGR. Growth is propelled by regulatory reforms that emphasize individual donor risk assessment, rapid adoption of automation, and the steady rebound in global donations. Wider use of multiplex nucleic-acid testing, the arrival of point-of-care molecular platforms, and expanding inventory-management algorithms are streamlining operations while improving pathogen detection. Meanwhile, cost pressures linked to compliance with evolving Laboratory Developed Test (LDT) rules are driving hospitals and blood banks to invest in integrated solutions that lower per-unit testing costs. Finally, pathogen-reduction technologies are starting to complement conventional screening, prompting incumbents to rethink R&D priorities and partnerships.

Global Blood Screening Market Trends and Insights

Rising blood donations leading to higher transfusion screenings

Group-donation campaigns, such as China’s 2025 initiative that rewards repeat donors, are reversing the pandemic dip in supply and creating fresh demand for scalable screening. A parallel shift by the United States Food and Drug Administration (FDA) to risk-based donor assessment removes categorical deferrals for men who have sex with men, enlarging the eligible pool while increasing the complexity of per-unit screening.^{[1]U.S. Food and Drug Administration, “Laboratory Developed Tests Regulatory Impact Analysis,” fda.gov} Together, higher volumes and donor diversity are encouraging blood establishments to adopt fully automated assays and robotics so that throughput rises without compromising sensitivity.

Greater prevalence of transfusion-transmissible infections

The Centers for Disease Control and Prevention (CDC) issued a 2025 alert after 13 million dengue cases occurred in the Americas during 2024, more than twice the prior year.^{[2]Centers for Disease Control and Prevention, “Ongoing Risk of Dengue Virus Infections,” cdc.gov}Concurrent West Nile outbreaks in Bulgaria and isolated monkeypox transmissions through platelet products underline the need for multiplex assays that go beyond the HIV-HBV-HCV triad. Rapid expansion of such panels has lifted demand for NAT reagents that can screen for emerging flaviviruses, orthopoxviruses, and region-specific pathogens within one workflow.

Stricter regulatory guidelines for blood safety

The new European Regulation (EU) 2024/1938 sets harmonized oversight standards effective 2027, while updated FDA guidance for blood establishments focuses on donor qualification, platelet collection and hepatitis B procedures.^{[3]AABB, “AI and Data Sciences in Blood Banking,” aabb.org} These rules accelerate investment in quality-management systems, automated documentation, and validated screening platforms. Vendors able to provide turnkey compliance features and audit-ready software modules gain a competitive edge.

Technological advances in screening methods

FDA approval of the cobas Malaria NAT test—the first molecular assay cleared for U.S. donors—illustrates regulators’ openness to high-sensitivity molecular diagnostics. Portable systems, such as Dragonfly, now deliver 96.1% orthopoxvirus sensitivity in under 40 minutes, making near-patient molecular testing viable. At the same time, metagenomic sequencing detects 74.0% of sepsis pathogens versus 41.1% by culture, offering a blueprint for future integrated blood-bank workflows.

High capital and consumable costs

Compliance with the newly finalized LDT rule will cost the U.S. screening sector an estimated USD 566 million to USD 3.56 billion each year, according to FDA modelling. Emerging economies struggle even more because NAT platforms require significant upfront spending and high-grade cold-chain reagents. Although microfluidic chips have driven per-test costs down to USD 9.5, overall affordability remains a challenge for smaller blood centres.

Limited skilled workforce and lab infrastructure

Expertise in molecular diagnostics is scarce outside tier-one hospitals. Rural Asia-Pacific labs face difficulties staffing technologists trained to run real-time PCR, interpret mNGS data, or maintain closed-system robotics. Without targeted training and tele-mentoring, decentralization may stall.

Segment Analysis

By Product: Reagents anchor revenue while smart instruments reshape workflows

Reagents and kits retained 56.12% of blood screening market share in 2024 due to recurring demand for NAT, immunoassay and confirmatory components. Their dominance is reinforced by batch-specific regulatory validation that locks in proprietary formulations. The instruments category is expanding at 10.02% CAGR as laboratories upgrade to fully automated NAT workcells and next-generation immunoassay analyzers that integrate robotic pipetting, bar-code tracking and LIS connectivity.

A surge in AI-enabled middleware is also notable; OneBlood’s deployment cut inventory levels by 40%, proving the operational value of real-time analytics. Software & services revenues therefore accelerate as blood banks seek predictive dashboards and automated deviation reporting, a trend likely to outpace reagent growth beyond 2028. Meanwhile, the emergence of portable molecular diagnostic devices, typified by the Dragonfly platform, suggests that decentralized testing could further fragment the instruments sub-segment over the long term.

By Technology: NAT leads today, NGS rises fastest

NAT maintained a robust 42.36% share of the blood screening market in 2024 as its capacity to detect viral nucleic acids during window periods remains unmatched for HIV-1/2, HBV and HCV. Nevertheless, next-generation sequencing is scaling quickly at an 11.35% CAGR. mNGS can uncover unexpected pathogens, pinpoint co-infections and support genomic surveillance during outbreaks, evidenced by a 74.0% detection rate in sepsis studies.

Traditional enzyme immunoassays (ELISA/CLIA) still dominate in lower-resource settings because of lower instrumentation costs and simpler workflows. Rapid tests fill emergency needs but struggle with sensitivity versus NAT. Western blot retains a niche for confirmatory HIV workups. As AI tools mine large molecular datasets, labs may unify NAT and NGS within a common informatics layer, eventually blurring the boundaries between technologies.

By Screening Target: Infectious-disease panels outpace all other categories

Infectious-disease panels accounted for 49.46% of revenue in 2024 and will grow at a 12.46% CAGR through 2030. Dengue’s surge to 13 million cases in the Americas during 2024 drove immediate demand for flavivirus NAT panels. Widening West Nile and Zika footprints similarly elevate the need for multiplex assays.

Blood-group typing continues to be indispensable for compatibility, while rare-antigen genotyping serves complex transfusion cases, especially in multi-ethnic populations. Roche’s cobas Malaria test, cleared in 2024, broadens screening for travelers and immigrants from endemic areas. Taken together, these advances reinforce the case for syndromic panels capable of processing multiple targets in a single run, streamlining both cost and logistics.

By End-User: Blood banks remain central, clinical labs race ahead

Blood banks processed 58.81% of global donations in 2024, reflecting their integrative role in collection, testing, processing and distribution. Yet testing decentralization is accelerating: clinical laboratories will expand at 10.56% CAGR to 2030 as hospital networks outsource specialty NAT and mNGS work to reference labs equipped with high-throughput sequencers.

University Hospitals Blood Bank recorded a 7% rise in samples and activated 323 massive-transfusion protocols in 2024, illustrating the growing testing burden on tertiary centers. Private-sector consolidation is also reshaping the end-user landscape, highlighted by Quest Diagnostics’ USD 985 million purchase of LifeLabs to extend advanced diagnostics into Canada. Plasma-fractionation facilities continue to demand stringent viral clearance, sustaining high-specificity NAT reagent consumption.

Geography Analysis

North America held 35.47% of the blood screening market in 2024. The FDA’s risk-based donor eligibility guidance, AI-assisted inventory management, and ongoing implementation of LDT oversight collectively maintain the region’s technology edge. Canada’s diagnostics sector expanded after Quest Diagnostics took full control of LifeLabs, deepening molecular-testing capacity and cross-border sample logistics. Meanwhile, Mexico is improving rural donation infrastructure, which lifts demand for mid-tier immunoassay analyzers.

Asia-Pacific is the growth engine, projected at a 10.15% CAGR to 2030. Japan’s 2025 hemoglobin-vesicle trial—the world’s first artificial-blood clinical study—could eventually reduce dependence on donor supply and lengthen storage life to two years at room temperature. India’s Quick Vitals facial-scan platform delivers non-invasive hemogram readouts within a minute and is being piloted in public hospitals, underscoring the region’s openness to disruptive diagnostics. China’s national carrier rate of 8.95% for thalassemia points to substantial prenatal and donor screening volume, while ongoing group-donation campaigns expand collection points in second-tier cities.

Europe shows steady progress under Regulation (EU) 2024/1938, which pools oversight across member states and allocates funds for crisis readiness. Germany and France are trial-ling pathogen-reduced platelets alongside traditional screening, whereas Bulgaria’s West Nile outbreak prompted expanded NAT panels at regional blood bank. The regulation’s unified guidance will streamline vendor approvals, encouraging pan-European platform standardization.

Competitive Landscape

Major suppliers—Roche, Abbott, Grifols and bioMérieux—pursue end-to-end platforms rather than stand-alone tests. Roche gained first-mover status with FDA-approved malaria NAT, while bioMérieux’s EUR 111 million SpinChip purchase strengthens the firm’s 10-minute, point-of-care portfolio. Grifols is doubling investment in its NAT business to ward off competition from emergent NGS-based services.

The arrival of pathogen-reduction technologies heightens rivalry by offering an alternative safety layer that could eventually trim the number of individual assays per donation. At the same time, AI-driven middleware and cloud inventory platforms invite non-traditional players from the software sector into the blood screening industry, intensifying competition for data ownership.

Regulatory hurdles may consolidate the market: mandated LDT submissions and hefty post-market surveillance fees could marginalize small independent labs, pushing them toward alliances or acquisition. Simultaneously, emerging manufacturers in India and China are scaling reagent production for domestic use, signaling a potential shift in global supply dynamics within five years.